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Abstract
Introduction: Alzheimer’s disease (AD) is the most dominant neurodegenerative disorder that causes dementia,
and no effective treatments are available. To study its pathogenesis and develop therapeutics, animal models
representing its pathologies are needed. Although many animal species develop senile plaques (SP) composed of
amyloid-β (Aβ) proteins that are identical to those found in humans, none of them exhibit neurofibrillary tangles
(NFT) and subsequent neurodegeneration, which are integral parts of the pathology of AD.
Results: The present study shows that Aβ accumulation, NFT formation, and significant neuronal loss all emerge
naturally in the hippocampi of aged domestic cats. The NFT that form in the cat brain are identical to those seen in
human AD in terms of their spatial distribution, the cells they affect, and the tau isoforms that comprise them.
Interestingly, aged cats do not develop mature argyrophilic SP, but instead accumulate intraneuronal Aβ oligomers
in their hippocampal pyramidal cells, which might be due to the amino acid sequence of felid Aβ.
Conclusions: These results suggest that Aβ oligomers are more important than SP for NFT formation and the
subsequent neurodegeneration. The domestic cat is a unique animal species that naturally replicates various AD
pathologies, especially Aβ oligomer accumulation, NFT formation, and neuronal loss.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative dis-
order characterized by three major pathologies: senile
plaques (SPs), neurofibrillary tangles (NFTs), and neur-
onal loss. The former two are extracellular and intracel-
lular argyrophilic aggregates composed of amyloid β
(Aβ) and hyperphosphorylated tau protein, respectively.
Accumulating evidence indicates that Aβ accumulation
leads to NFT formation and subsequent neuronal loss
and cognitive dysfunction [24, 29, 47]. Based on this no-
tion, various transgenic (Tg) mouse models have been
generated by introducing human APP (amyloid precursor
protein) or PSEN (presenilin) with the mutations linked to
familial AD [23]. These Tg mice produce human Aβ be-
yond physiological levels, leading to massive formation of
SPs [13]. Nevertheless, they fail to develop NFTs and
neuronal loss unless mutant MAPT (tau) is simultan-
eously introduced. Although wild-type mice do not spon-
taneously form SPs or NFTs, many other animal species
such as monkeys and dogs are known to develop SPs as
they age [19, 25, 44, 48, 58]. However, these animals do
not display NFTs and neuronal loss. If an animal species
can be identified that naturally develops SPs, NFTs, and
neuronal loss, it could be a desirable animal model for
translational studies of AD. Hyperphosphorylated tau
(AT8-positive) has been observed in the brains of domes-
tic cats with signs of neurological dysfunction [18, 26].
Furthermore, recently, we found that aged leopard cats
and cheetahs display both Aβ deposits and NFTs in the
brains [8, 49]. Leopard cats and cheetahs are endangered
wild animals, thus they are not adequate for further la-
boratory examination. In contrast, domestic cats, which di-
verged from a common ancestor with the leopard cat and
cheetah approximately 6.2 million years ago [32], could be
used in such studies if they produce Aβ deposits and NFT.
Here, we report that aged domestic cats naturally
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accumulate Aβ oligomers, produce NFT, and moreover
suffer hippocampal neuronal loss, and thus, could serve as
a valuable animal model of human AD.
Materials and methods
Brain samples
Cat brain tissues of various ages were examined (Table 1).
All the adult cat brains were obtained through routine
necropsies performed at the Department of Veterinary
Pathology, the University of Tokyo. The fetal brain samples
were purchased from a laboratory animal supplier
(Nisseiken Co. Ltd., Tokyo, Japan). All procedures were
done according to the institutional regulations for animal re-
search. One hemisphere of the brain was fixed in 10 %
phosphate-buffered formalin, and the other hemisphere was
coronally sectioned and then frozen at −80 °C until use.
Histology
Formalin fixed paraffin-embedded tissues were cut into 4-
μm-thick serial sections. The deparaffinized sections were
then stained with HE, periodic acid-methenamine silver,
Congo red and the Gallyas-Braak method. Digital im-
ages were obtained using an Olympus BX 50 micro-
scope (Olympus, Tokyo, Japan) equipped with a Nikon
DS-Ri1 digital camera (Nikon, Tokyo, Japan).
Immunohistochemistry
Consecutive sections were stained using the immu-
noenzyme technique. Sections were deparaffinized and
rehydrated. Antigen retrieval was done by heating or
with FA (for Aβ). The sections were immersed in 1 %
hydrogen peroxide in methanol for 20 min in order to
deactivate endogenous peroxidases, and then immersed
in 5 % skim milk in Tris-buffered saline (TBS) in order
to avoid nonspecific binding of the antibody. The
following primary antibodies were used: mouse anti-
hyperphosphorylated-tau Ser202/Thr205 (clone AT8,
1:100, Thermo Scientific, Rockford, IL), mouse anti-
hyperphosphorylated-tau Ser212/Thr214 (clone AT100,
1:100, Thermo Scientific), mouse anti-3-repeat-tau RD3
(clone 8E6/C11, 1:100, Millipore, Temecula, CA), mouse
anti-4-repeat-tau RD4 (clone 1E1/A6, 1:100, Millipore),
rabbit anti-pan-tau (1:100, Sigma, St. Louis, MO), mouse
anti-Aβ42 (clone 12 F4, 1:1000, Millipore), rabbit anti-
Aβ42 (1:1000, IBL, Gunma, Japan), rabbit anti-AβN1
(1:100, IBL), rabbit anti-AβpN3 (1:100, IBL), rabbit anti-
Ubiquitin (1:200, Dako, Carpinteria, CA), rabbit anti-
Apolipoprotein (Apo) E (A299, 1:100, IBL), and mouse
anti-NeuN (clone A60, 1:100, Millipore). After incubation
with each primary antibody at 4 °C overnight, immunola-
beled antigens were visualized using the Dako Envision +
System (Dako). In brief, the sections were incubated with
the secondary antibody linked to a peroxidase-conjugated
polymer backbone at 37 °C for 40 min, reacted with 0.05 %
3′3-diaminobenzidine plus 0.03 % hydrogen peroxide in
Tris-hydrochloric acid buffer, and then counterstained
with hematoxylin. Negative controls were obtained by
omitting the primary antibodies. Neuronal loss in the
pyramidal cell layer of the hippocampal CA1 region
was evaluated by counting NeuN-positive cells dis-
played in Fig. 6a. Comparisons of the means among
the three groups were performed with one-way ANOVA
followed by Tukey's HSD test using SPSS software (IBM,
Tokyo, Japan). Differences with a P value of <0.05 were
considered significant.
Double-labeling immunofluorescence
Sections were deparaffinized and rehydrated. Antigen
retrieval was done by heating. In order to reduce auto-
fluorescence, Sudan black B treatment was performed.
Sections were immersed in 5 % skim milk in TBS. After
Table 1 Age, sex and immunohistochemical results for Aβ42
and hyperphosphorylated tau in cats
No. Age Sex Aβ42 HP-tau
1 fetus (50 days) F − +a
2 fetus (50 days) M − +a
3 2-week-old F − −
4 2-week-old F − −
5 3-year-old M − −
6 3-year-old M − −
7 4-year-old F − −
8 4-year-old F − −
9 5-year-old F − −
10 8-year-old F + −
11 14-year-old F − −
12 14-year-old M + ++
13 15-year-old F + +
14 15-year-old M + −
15 15-year-old ND + −
16 16-year-old F + −
17 16-year-old M + −
18 17-year-old F + −
19 17-year-old F + +
20 17-year-old ND + +
21 18-year-old F + +
22 19-year-old F + ++
23 20-year-old F + +
24 20-year-old ND + ++
25 22-year-old M + +
Aβ42: -, negative; +, small aggregates of Aβ42 were observed in the parietal
and temporal cortices on FA-pretreated sections, and intracellular aggregates
of Aβ 42 were observed in the cytoplasm of hippocampal pyramidal cells.
HP-tau: -, negative; +, AT8-positive cells limited to the entorhinal cortex; ++,
AT8-positive cells in the entorhinal cortex and throughout the hippocampus. F,
female; M; male, ND, no data; a, weak AT8 positivity on the surface of
cerebral cortex
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incubation with each of the primary antibodies at 4 °C
overnight, the sections were washed with TBS. The sec-
tions were then incubated with corresponding secondary
antibodies at 37 °C for 1 h, mounted with Vectashield
(H-1500, Vector Laboratories, Burlingame, CA), and ex-
amined under a Leica DMI 3000B fluorescence micro-
scope (Leica Microsystems, Tokyo, Japan) or a Carl Zeiss
LSM700 Confocal Laser Scanning Microscopy (Carl Zeiss,
Tokyo, Japan). Primary antibodies used were as follows:
mouse anti-hyperphosphorylated-tau Ser202/Thr205
(clone AT8, 1:100, Thermo Scientific), rabbit anti-MAP2
(1:1000, Millipore), rabbit anti-GFAP (1:400, Dako), rabbit
anti-Olig2 (1:200, Millipore), mouse anti-RAB9 (clone
Mab9, 1:100, LSBio, Seattle, WA), and rabbit anti-Aβ42
(1:100, IBL). Secondary antibodies used were as follows:
ALEXA594-conjugated goat anti-mouse IgG (1:100,
Invitrogen, Eugene, OR), ALEXA488-conjugated goat
anti-rabbit IgG (1:100, Life Technologies, Eugene, OR),
ALEXA594-conjugated goat anti-rabbit IgG (1:100, Life
Technologies), and ALEXA488-conjugated goat anti-
mouse IgG (1:100, Invitrogen).
Transmission electron microscopy
Formalin fixed hippocampal tissues with NFTs (confirmed
by Gallyas-Braak method) were cut into 1-mm cubes and
then post-fixed with 2 % osmium oxide in phosphate
buffer (100 mM, pH 7.2) at 4 °C for 1 h. After washed in
phosphate buffer, the tissues were dehydrated in a graded
series of ethanol, displaced by propylene oxide and then
embedded in Spurr resin (Spurr Low Viscosity Embedding
Kit, Polysciences, Warrington, PA). Ultrathin sections
(70-nm-thick) were stained with 4 % uranyl acetate in
distilled water and Reynolds’ lead citrate, and then ex-
amined with a JEM-1010 transmission electron micro-
scope (JEOL, Tokyo, Japan).
Protein extraction
For tau extraction, hippocampal tissues were homogenized
in four volumes of TBS containing a protease inhibitor
cocktail (cOmplete Mini, Roche, Mannheim, Germany) and
a phosphatase inhibitor cocktail (PhosSTOP, Roche) and
fractioned by three-step ultracentrifugation including TBS,
sarkosyl (sodium N-dodecanoylsarcosinate) and guanidine
hydrochloride (GuHCl) extraction, essentially as described
previously [21]. For the dephosphorelation assay, phosphat-
ase inhibitor cocktail was omitted. In brief, the homoge-
nates were centrifuged at 125,000 × g at 4 °C for 1 h, and
the supernatants were harvested as TBS-soluble fractions.
The precipitates were dissolved by sonication in four
volumes of 1 % sarkosyl in TBS containing the protease
inhibitor cocktail and the phosphatase inhibitor cocktail,
and then the solutions were incubated at room temperature
(RT) for 1 h. After centrifugation at 125,000 × g at RT for
15 min, the supernatants were removed. The sarkosyl-
insoluble precipitates were then dissolved by sonication in
two volumes of 4 mol/L GuHCl and incubated at RT for
1 h. After a second centrifugation at 125,000 × g at RT for
15 min, the supernatants were harvested, and the solvent
(4 mol/L GuHCl) was exchanged with TBS containing the
protease inhibitor cocktail and the phosphatase inhibitor
cocktail using Amicon Ultra 10 K filter devices (Millipore).
For Aβ extraction, hippocampal and parietal cortex tis-
sues were homogenized in four volumes of TBS containing
the protease inhibitor cocktail and fractioned by three-step
ultracentrifugation including TBS, SDS, and FA extraction.
In brief, the homogenates were centrifuged at 100,000 × g
at 4 °C for 1 h, and the supernatants were harvested as
TBS fractions. The precipitates were dissolved in four vol-
umes of 2 % SDS in TBS containing the protease inhibitor
cocktail, centrifuged at 100,000 × g at RT for 1 h, and the
supernatants were harvested as SDS fractions. The precipi-
tates were finally dissolved in 70 % FA in water. After cen-
trifugation at 100,000 × g at RT for 1 h, the supernatants
were harvested as FA fractions. The TBS and SDS fractions
were diluted 10- and 20-fold, respectively, in TBS contain-
ing the protease inhibitor cocktail, and the FA fractions
were neutralized by 1:10 dilution into 1 M Tris solu-
tion, pH 11. The protein concentrations of the resultant
solutions were determined by the BCA protein assay
(Thermo Scientific).
Western blotting
For tau analysis, extracts of the hippocampus were incu-
bated with alkaline phosphatase mix (500 mM Tris–HCl
pH 9.0, 500 mM MgCl2, 0.1 M DTT (Invitrogen), 10,000U/
ml calf intestinal alkaline phosphatase (New England
Biolabs, Ipswich, MA)) at 37 °C overnight for dephos-
phorylation. Subsequently, aliquots (5 μg protein) were
electrophoresed on 4-12 % Bolt Bis-Tris Plus gel (Thermo
Fisher Scientific, Waltham, MA) and transferred to 0.45-
μm PVDF membranes (Millipore). Nonspecific binding
was blocked with 5 % skim milk in TBS containing Tween
20 (TBS-T, 20 mM Tris–HCl buffer, pH 7.0, containing
50 mM NaCl and 0.1 % Tween 20) for 30 min. The fol-
lowing primary antibodies were used: mouse anti-tau
(clone TAU-5, 1:1000, Life Technologies), RD3 (clone
8E6/C11, 1:1000, Millipore), and RD4 (clone 1E1/A6,
1:1000, Millipore). Alkaline phosphatase-conjugated anti-
mouse IgG was then applied. The blotting signals were
visualized with 5-bromo-4-chloro-3'-indolylphosphatase
p-toluidine salt/nitro-blue tetrazolium chloride (BCIP/
NBT) and imaged with an Image Quant LAS 4000 mini
bio-molecular imager (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden). For Aβ analysis, aliquots (50 μg
protein) of the TBS and SDS fractions were electro-
phoresed on 4-12 % Nupage Bis-Tris polyacrylamide
gels (Life Technologies) and transferred to 0.45-μm PVDF
membranes (Millipore). Nonspecific binding was blocked
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with 5 % skim milk in TBS containing Tween 20 for
30 min. Mouse anti-Aβ antibody (clone 6E10, 1:3000),
mouse anti-Aβ antibody (clone 82E1, 1 μg/ml, IBL) and
rabbit anti-ApoE antibody (A299, 5 μg/ml, IBL) were
used as the primary antibody. Horseradish peroxidase-
conjugated secondary antibody (1:5000, Dako) was then
applied. The blotting signals were visualized with the
chemiluminescence ECL Select Western Blotting Detec-
tion Kit (GE Healthcare Bio-Sciences AB) and imaged
with an Image Quant LAS 4000 mini bio-molecular
imager (GE Healthcare).
Dot blot
For dot blot immunoanalysis, aliquots (50 μg protein)
of the TBS, SDS, and FA fractions were dotted onto
0.45-μm PVDF membranes (Millipore) in a dot-blot
apparatus (Bio-Rad). The blots were probed with a
polyclonal antibody A11 specific for amyloid oligo-
mers (1:1000, Biosource, Camarillo, CA) [35], followed
by alkaline phosphatase–conjugated goat anti-rabbit
antibody (1:5000, Thermo Scientific), and visualized
with the BCIP/NBT detection system (Wako Chemicals,
Osaka, Japan).
ELISA
To quantify the amount of Aβ oligomers in the extracts
from cat brains, we used our originally developed BAN50
single-antibody sandwich ELISA that is specific for high
molecular weight Aβ oligomers (10- to 20-mers) in quad-
ruplicate [16]. The buffers and assay procedures were
similar to those described previously [34]. As a standard
for inter-plate calibration, we used a ‘multiple antigenic’
peptide (MAP). MAP is a synthetic peptide that consists
of 16 copies of epitope peptide (corresponding to
Aβ1-10) recognized by anti-Aβ monoclonal antibody
(BAN50) and a single lysine core to which the epi-
tope peptides are linked [34]. The SuperSignal ELISA
Femto Maximum Sensitivity Substrate (Thermo Scien-
tific) and a luminometer (SpectraMaxL, Molecular
Devices, Osaka, Japan) were used for signal detection.
Results
Aβ pathology in the cat brain
In the present study, we investigated domestic cats at vari-
ous ages for AD pathologies. By immunohistochemical
analysis with anti-Aβ42 antibody (12 F4), we found that
domestic cats older than 8 years displayed Aβ deposits
(Table 1). There were cases with Aβ deposits that were
not associated with tau immunoreactivity but there were
no case with tau positive tangles in the absence of Aβ de-
posits. On formic acid (FA)-pretreated sections, extracel-
lular small granular Aβ aggregates were observed in the
neuropil throughout the cerebral cortex but rarely in the
hippocampus (Fig. 1a, Additional file 1: Figure S1a). These
parenchymal Aβ deposits in cat brains had no central core
as seen in mature plaques of human AD and Tg mouse
models of AD, and were not visualized by silver staining
or Congo red staining. Also, vascular Aβ deposition and
neuritic alterations were absent. As it has been previously
demonstrated [11, 26], full-length Aβ1-42 aggregates in
the cat brains were not stained with Aβ N-terminal anti-
body anti-AβN1 (Fig. 1a). In addition, unlike typical SPs in
human, monkey and dog brains [7, 15], Aβ aggregates in
the cat brains were not stained with antibody against N-
terminally truncated Aβ (AβpN3). ApoE protein coloca-
lized with the small granular Aβ aggregates in the cerebral
cortex (Fig. 1b). In contrast to the staining pattern of Aβ
in the cerebral cortex, on heat-pretreated sections, intra-
cellular accumulation of Aβ was detected predominantly
in the pyramidal cells of the hippocampal CA1 to CA3 re-
gion but rarely in the cerebral cortex (Fig. 1c, Additional
file 1: Figure S1b). ApoE immunopositivity was not de-
tected in this area. These intracellular Aβs co-localized
with Rab9 under confocal laser scanning microscopy, indi-
cating their localization in late endosomes (Fig. 1d). The
FA-vulnerable intracellular Aβs in the hippocampus always
coincided with FA-resistant parenchymal Aβ deposits in
the cerebral cortex. The different states of Aβ aggregation
between the hippocampus and cerebral cortex may be due
to the different neuronal cell types and/or different environ-
ments surrounding neurons in these regions. Dot blot ana-
lysis using amyloid oligomer-specific A11 antibody revealed
the existence of Aβ oligomers in SDS-soluble fractions, but
not in FA-soluble fractions, prepared from hippocampal tis-
sues of aged cats (Fig. 1e). Considering the vulnerability to
FA treatment, these Aβ oligomers were presumably derived
from the intracellularly accumulated Aβs observed in
immunohistochemistry. Western blotting analysis using
anti-Aβ antibody 6E10 indicated two distinct bands with
molecular sizes of approximately 24 kDa and 54 kDa, which
corresponded to Aβ hexamers and dodecamers, respect-
ively, in the SDS-soluble fractions (Fig. 1f). The band corre-
sponding to Aβ dodecamer was detected by anti-Aβ
antibody 82E1, an antibody that does not react with APP
(Additional file 1: Figure S2a). Neither of the bands corre-
sponding to Aβ hexamers or dodecamers was detected with
anti-ApoE antibody, indicating that these oligomers are not
bound with ApoE (Additional file 1: Figure S2b). The pres-
ence of Aβ oligomers in the SDS-soluble fractions was also
confirmed by enzyme-linked immunosorbent assay (ELISA)
specific for high molecular weight Aβ oligomers including
Aβ dodecamer (Additional file 1: Figure S1c).
Spatial and temporal expression of tau isoforms in the
cat brain
We next examined tau pathology in cat brains. Initially,
we studied the expression pattern of tau isoforms among
different ages. In immunohistochemistry with RD3 and
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RD4 antibodies specific to 3-repeat (3R) and 4-repeat
(4R) tau, respectively, fetal cats were shown to express
only 3R tau throughout the cerebrum (Fig. 2). The
hippocampal pyramidal cells began to express 4R tau at
2 weeks postnatal age (Additional file 1: Figure S3a). In
adult brains (3- to 22-year-old), both 3R and 4R tau were
detected. We next investigated tau hyperphosphoryla-
tion by immunohistochemistry with AT8 (anti-pSer202/
pThr205-tau) and AT100 (anti-pThr212/pSer214-tau)
antibodies. All of the cats without Aβ deposits were
negative for hyperphosphorylated tau, except in fetal
cats AT8-positive staining was detected in the surface
Fig. 1 Aβ deposits in cat brains. a Aβ42 aggregates are detected in the parenchyma of the cerebral cortex with anti-Aβ42 antibody (12 F4) on formic
acid (FA)-pretreated sections but not on heat-pretreated sections. These aggregates are not detected with antibodies against the N-terminus of human
Aβ (AβN1 and AβpN3). b Aβ42 aggregates in the cerebral cortex colocalized with ApoE. c Heat pretreatment revealed intracellular Aβ42 aggregates in
the pyramidal cells of the hippocampus but not in the cortex. d Some of the intracellular Aβ42 (red) aggregates colocalized with Rab9 (green). Black
bars = 50 μm, white bar = 10 μm. e Dot blot analysis of SDS fractions and FA fractions of cortex (Ctx) and hippocampus (Hpc) of young cats and aged
cats. Aβ oligomers were detected with A11 antibody, predominantly in the SDS fraction from the hippocampus of aged cats. f Western
blotting analysis of the SDS fraction of the Ctx and Hpc of young cats and aged cats. Two distinct bands were detected with anti-Aβ
antibody 6E10 in the brains of aged cats: approximately 24 kDa and 54 kDa, indicating Aβ hexamers and dodecamers, respectively
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layer of the cerebrum (Table 1, Additional file 1: Figure
S3b). In some of the aged cats with Aβ deposits (over
14 years old), AT8-positive staining was detected within
neurons (Table 1). In mild cases, a few AT8-positive
cells were observed in the entorhinal cortex (Fig. 3a),
and in more severe cases, numerous AT8-positive cells
were detected throughout the entorhinal cortex, hippo-
campus and also mildly in the cerebral cortex (Figs. 2,
3b, Table 1). Also, a few AT8-positive cells were ob-
served in the locus ceruleus of aged cats (Fig. 3b). We
noticed that the cerebrums were atrophied in aged cats
compared to those in young cats (Fig. 2). The age-
dependent change in tau isoform expression was con-
firmed with western blotting with anti-tau (TAU-5), RD3,
and RD4 antibodies of TBS-soluble fractions prepared
from the cerebrums (Fig. 4a). Western blotting analysis
Fig. 2 Immunohistochemical analysis of tau isoforms and their phosphorylation status in cat brains. Immunohistochemistry for 3-repeat tau (RD3),
4-repeat tau (RD4), and hyperphosphorylated-tau (AT8) in the developing cat (Fetus, case No. 1 shown in Table 1), adult cat (4 years (yrs) old, case
No. 7), and aged cat (19 yrs old, case No. 22) brains. Only the 3-repeat tau isoform is expressed in the fetal cat brain, whereas both 3-repeat and
4-repeat tau isoforms are expressed in the developed cat brains. Abundant AT8-positive hyperphosphorylated tau aggregates are observed in the
hippocampus and entorhinal cortex of the aged cat brain. Bar = 5 mm
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with AT8 and AT100 antibodies indicated that sarkosyl-
insoluble, guanidine HCl-soluble fractions prepared from
hippocampal tissues of aged cats contained abundant
hyperphosphorylated tau (Fig. 4b). These insoluble tau
species, which showed a smear profile in western blots,
were shown to consist of both 3R and 4R tau isoforms,
which was proven after dephosphorylation of the sam-
ples (Fig. 4b).
NFT in aged cat brains
The presence of hyperphosphorylated tau in insoluble
brain fractions implies that these tau proteins may form
NFTs. Thus, we examined NFT formation in aged cats by
Gallyas-Braak silver staining and confirmed silver positive
fibrillar aggregates in the neuronal somata and in neurites
(Fig. 5a). By electron microscopy, bundles of filaments
were observed in the neuronal somata and neurites
(Fig. 5b). These filaments had widths of 15-25 nm and
showed either straight pattern or paired twisted pattern.
In the twisted area, lengths between the constrictions were
80-100 nm. These ultrastructural findings were compar-
able to those of NFTs in AD [2], although the lengths
between the constrictions of the paired twisted filaments
tend to be a little longer than in AD. Abundant NFTs were
found in the hippocampus (Fig. 5c), but rarely in the cere-
bral cortex (Fig. 2), of aged cats. Notably, this distribution
Fig. 3 Hyperphosphorylated tau accumulation in the entorhinal cortex and locus ceruleus of cat brains. a Immunohistochemistry of the entorhinal
cortex of a cat with mild hyperphosphorylated tau accumulation (15-year-old, case No. 13) for hyperphosphorylated-tau (AT8). The neuronal soma and
dendrites are positively stained for hyperphosphorylated tau. Bar = 20 μm. b Immunohistochemistry of the entorhinal cortex and locus ceruleus of a
cat with severe hyperphosphorylated tau accumulation (14-year-old, case No. 12) for AT8, 3-repeat tau (RD3), and 4-repeat tau (RD4).
AT8-positive aggregates are also positively stained for 3-repeat tau and 4-repeat tau on consecutive sections. Bar = 300 μm
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of NFTs in aged cat brains corresponded to that of intracel-
lular Aβ oligomers. In consecutive sections, NFTs were co-
localized with hyperphosphorylated tau (AT8 and AT100)
and ubiquitin (Fig. 5c). Regarding the affected cell types,
hyperphosphorylated tau was detected mainly in neurons
(MAP2-positive) and in some oligodendrocytes (Olig2-
positive), but not in astrocytes (GFAP-positive) (Fig. 5d).
Aggregates in the oligodendrocytes were also detected by
Gallyas-Braak staining (Fig. 5a). The absence of astrocytic
tau inclusion bodies, such as astrocytic plaques or tuft-
shaped astrocytes, indicates that the hyperphosphorylated
tau aggregates found in feline brains differ from those
Fig. 4 Western blotting analysis of tau isoforms and their phosphorylation status in cat brains. a Western blotting of TBS-soluble fractions obtained
from the hippocampus of various ages and treated with alkaline phosphatase (AP). The left lane (tau) shows the six isoforms of human
tau (recombinantly produced): three 3-repeat tau isoforms (2N3R, 1N3R, 0N3R) and three 4-repeat tau isoforms (2N4R, 1N4R, 0N4R). In the
fetal brain, only the 3-repeat tau isoforms are expressed. In the adult cat brains, all six isoforms are detected using anti-tau antibody
(TAU-5) and also 3-repeat tau (RD3), and 4-repeat tau (RD4) antibodies. b Western blotting of sarkosyl-insoluble guanidine HCl-soluble
fractions obtained from the hippocampus of aged cat brains without AP treatment (left) and with AP treatment (right). In cat hippocampi
that were immunohistochemically positive for hyperphosphorylated tau (cases No. 12 and 22), AT8- and AT100-positive tau proteins are
detected. In these cats, the smear-like band pattern resolved into clear lower molecular weight bands consisting of both 3-repeat and
4-repeat tau isoforms after dephosphorylation treatment
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associated with corticobasal degeneration and progressive
supranuclear palsy [28].
Hippocampal neuronal loss in cats with NFT
Although neuronal loss in the entorhinal cortex and
hippocampus is considered to be an early event in AD
[22, 59], it has not been detected in combination with
Aβ and tau pathologies in non-human species [50, 58].
Because hippocampal neurodegeneration is important in
the manifestation of AD [30], we assessed neuronal loss
in the hippocampus of the cats. The number of NeuN-
positive cells in the hippocampal CA1 region were com-
pared among three groups: young cats with neither Aβ
deposits nor NFTs (Aβ-/NFT-, n = 3, mean age 3.7 years
old), aged cats with only cerebral Aβ deposits but no
hippocampal NFTs (Aβ+/NFT-, n = 3, mean age 18.0 years
old), and aged cats with both cerebral Aβ deposits and
hippocampal NFTs (Aβ+/NFT+, n = 3, mean age 17.6 years
old). In the Aβ+/NFT- group, NeuN-positive cells were
slightly but not significantly decreased compared to
those in the Aβ-/NFT- group (P = 0.076, Fig. 6a, b),
whereas the Aβ+/NFT+ group showed a significant
decrease in NeuN-positive cells compared to the other
two groups (P < 0.001, Fig. 6a, b). Ghost tangles were
visible on HE-stained sections suggesting the death of
tangle bearing neurons (Fig. 6c, black arrows). These
dead neurons were negative for NeuN and the live
cells were positive for NeuN. Also, inclusions com-
posed of hyperphosphorylated tau (AT8- and AT100-
positive on consecutive sections) were occasionally
Fig. 5 NFTs in aged cats brains. a Gallyas-Braak staining-positive argyrophilic aggregates are observed mainly in the neuronal soma, neurites, and
also in some oligodendroglial cells (green arrowhead) in the entorhinal cortex of aged cat brain. Bar = 20 μm. b Transmission electron microscopy
of NFT in the hippocampus. Bundles of filaments are observed in the neuronal soma either in strait form or paired twisted form. For the paired
twisted form, the lengths between the constrictions (arrowheads) were 80-100 nm. Bars = 500 nm and 100 nm (inset). N: nucleus. c Consecutive
sections of hippocampus show AT8-, AT100-, and ubiquitin-immunopositivity for NFTs. Bar = 100 μm. d AT8-positive (red) hyperphosphorylated
tau is observed in MAP2-positive (green) neurons (left) and Olig2-positive (green) oligodendrocytes (right, white arrows), but not in GFAP-positive
(green) astrocytes (middle). Bar = 50 μm
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observed on HE-stained sections (Fig. 6c, inset, green
arrowheads).
Discussion
In this study, we found that aged domestic cats develop
not only Aβ deposits but also NFTs and neuronal loss in
their brains. Though it has been shown that NFT occurs
earlier than senile plaque in humans, in cats Aβ deposits
(diffuse plaques in the cerebral cortex and intracellular
Aβ oligomers in the hippocampus) started to occur at
8 years of age, and NFTs and neuronal loss at 14 years
of age. The distribution, affected cells, tau isoforms and
ultrastructure of the NFTs were comparable to those of
AD. NFT formation and subsequent neuronal loss oc-
curred in the same brain region as that of intracellular Aβ
oligomer accumulation, i.e., the hippocampus. These find-
ings have also been seen in Tg mouse models and human
AD patients [1, 17, 41, 57]. The early occurrence of these
pathologies makes this animal species an attractive model
for studying therapeutic intervention for AD.
What factors enable domestic cats to develop full AD
pathologies, particularly NFTs and neuronal loss, in its
shorter life-span than humans? Current evidence suggests
that Aβ and tau interact to accelerate each other’s path-
ology and that tau hyperphosphorylation and subsequent
NFT formation are induced by pathological Aβ species,
i.e., Aβ oligomers [3, 29]. Our results demonstrating that
NFTs formed in the same brain region as intracellular Aβ
oligomers in aged cats may imply the involvement of Aβ
oligomers in the initiation (early stage) of NFT develop-
ment. Furthermore, these Aβ oligomers consisted of Aβ
hexamers and dodecamers (Fig. 1c), which are considered
to be pathological Aβ species and to be associated with
pathological tau conformers in AD [3, 4, 37]. The accu-
mulation of Aβ oligomers in domestic cats presumably
comes from its Aβ sequence, in which the 7th amino
acid residue is different from that of human Aβ [5, 39]
(Additional file 1: Table S1). There are two known fa-
milial AD-linked mutations in the N-terminal region of
Aβ: the English mutation (H6R) and the Tottori muta-
tion (D7N), both of which result in increased formation
of Aβ oligomers [9, 43]. Also, racemization of the 7th
Asp residue affects the Aβ aggregation property and in-
hibits its fibril formation [53]. Thus, the substitution of
the 7th amino acid of human Aβ likely results in en-
hanced oligomerization and reduced fibrilization of Aβ,
which may explain why cat Aβ abundantly accumulates
into oligomeric forms.
This study demonstrated that domestic cats develop
non-argyrophilic small granular Aβ aggregates in the
cerebral cortex and FA-vulnerable intracellular Aβ oligo-
mers in the hippocampus, but not argyrophilic SPs.
ApoE colocalized with the non-argyrophilic Aβ aggre-
gates in the cerebral cortex that lack immunoreactivity
Fig. 6 Hippocampal neuronal loss in cats with NFTs. a Immunohistochemistry for NeuN in young cats (Aβ–/NFT–, n = 3, mean age 3.7 years old),
aged cats with Aβ deposits but no NFTs in the hippocampus (Aβ+/NFT–, n = 3, mean age 18 years old), and aged cats with Aβ deposits and NFTs
(Aβ+/NFT+, n = 3, mean age 17.6 years old). Bar = 100 μm. b The number of NeuN-positive pyramidal cells shown in (a). The number of hippocampal
neurons is significantly decreased in aged cats with Aβ deposits and NFTs (Aβ+/NFT+) compared to young cats (Aβ–/NFT–) and aged cats
with Aβ deposits but no NFTs in the hippocampus (Aβ+/NFT–). *P < 0.001. c Ghost tangles are observed on an HE-stained section (arrows). In some of
the cells, inclusions (composed of hyperphosphorylated tau, confirmed on consecutive sections) were observed (inset, arrowheads). Bar = 25 μm
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against anti-Aβ N-terminus antibodies. The same finding
has been described with newly formed Aβ deposits in the
human brain indicating that the N-terminal epitope of the
Aβ is bound with ApoE [51]. We consider that the lack of
SP formation is important for the early development of
NFTs in cat brains. Many animal species including mon-
keys, dogs, bears, camels, and horses, whose Aβ sequence
is identical to that of human Aβ (Additional file 1: Table
S1), spontaneously develop abundant argyrophilic SPs
similar to human SPs in old age, but do not develop NFTs
[6, 15, 33, 40, 48, 56, 58]. It is known that the extent of
intraneuronal Aβ42 labeling is inversely correlated with
the progression of SP in double Tg (APPSWE/London and
mutant PS1 M146L) and triple Tg (APPSWE, tauP301L, and
PS1M146V knock-in) mice, suggesting that the amount of
intraneuronal soluble Aβ is in equilibrium with the
amount of extraneuronal insoluble fibrillar Aβ [36, 42].
Furthermore, the number of Aβ oligomers present within
the brain is inversely correlated with the severity of SP in
aged dogs [25]. Thus it has been proposed that SPs are
formed to sequester toxic Aβ oligomers, preventing Aβ
oligomer-induced pathologies including NFT formation
[3]. In animal species that express human-type Aβ, SPs
may be gathering toxic Aβ oligomers as “trash bins”, pre-
venting Aβ oligomers from interacting with tau and pro-
ceeding to NFT formation [12, 38, 52] (Table 2). Uniquely
among animals, humans have extended their life-span to
overwhelm the buffering capacity of SPs, and Aβ oligo-
mers that have overflowed SPs could cause tau patholo-
gies. In cats, on the other hand, the buffering stage (SP
formation) is skipped, and therefore, tau pathologies would
appear soon after Aβ oligomer formation in a shorter life-
span. A very similar type of Aβ to cat Aβ is known in hu-
man familial AD. Patients and Tg mice with the APP
Osaka (E693Δ) mutation, which corresponds to E22Δ in
the Aβ sequence, accumulate abundant Aβ oligomers
within neurons without developing SPs and showed early
cognitive dysfunction [54, 55]. Furthermore, when the Tg
mice were crossbred with tau-Tg mice expressing both 3R
and 4R human tau, the resultant double Tg mice develop
NFTs [57].
Besides the accumulation of Aβ oligomers, other factors
may also be involved in NFT formation in domestic cats.
We first assumed that the expression pattern of tau iso-
forms might influence NFT formation. The expression
patterns of 3R and 4R tau differ among animal species
and developmental stages [10, 20, 31]. In humans and
mice, only 3R tau isoforms are expressed in the fetal brain.
In adults, whilst both 3R and 4R tau isoforms are
expressed in humans, only 4R tau isoforms are expressed
in mice. As mentioned above, mice do not develop NFT,
but tau Tg mouse strains that express both 3R and 4R tau
isoforms do [57]. In the present study, we showed that
only 3R tau isoforms are expressed in the brains of fetal
cats, whereas both 3R and 4R tau isoforms were detected
in the brains of adult cats. Thus, the expression of both
3R and 4R tau isoforms seems to be a prerequisite for
NFT formation. However, chimpanzees, which also ex-
press both 3R and 4R tau isoforms in adult ages, do
not develop NFTs except in the case of brain infarction
[19, 23, 27, 44, 48]. We also considered the involvement of
the tau amino acid sequence. Mouse tau shows only 83 %
homology with human tau, whereas cat tau shows 93 %
homology with human tau (Table 2, Additional file 1:
Table S2). However, again, chimpanzees whose tau se-
quence is identical to that of human tau do not develop
NFTs. These observations suggest that tau isoform expres-
sion and the amino acid sequence may be important for
NFT formation, but the pathology does not simply depend
on either of these factors.
The present study detected intracellular Aβ accumu-
lation, NFT formation, and neuronal loss in the hippo-
campi of aged cats’ brains. However, no significant
neuronal loss was observed in the brains of cats that
were free from NFT, even when intracellular Aβ was
present (Fig. 6a, b). This implies that NFTs are import-
ant for hippocampal neurodegeneration, as has been in-
dicated in studies of human AD [30]. Some studies
have suggested that the toxic tau species is oligomers,
and NFTs are formed to sequester those oligomers [45].
If so, when NFTs are saturated, tau oligomers would
overflow causing neurodegeneration. This may explain
our observation that neuronal loss and NFTs were ob-
served in the same brain region.
In a previous report, AT8-positivity was detected in cats
with seizures [26]. In the present study, none of the cats
Table 2 Comparison of AD pathology in different species [5, 19, 25, 27, 31, 33, 39, 44, 48]
Species Life span Aβ Tau Neuron loss
Sequence vs. human Oligomers SP Sequence vs. human Isoformsa NFT
Human 80 yrs — Yes Yes — 3R + 4R (6) Yes Yes
Chimpanzee 60 yrs 100 % ND Yes 100 % 3R + 4R (6) No No
Dog 20 yrs 100 % Yes Yes 92 % 3R + 4R (4) No No
Cat 20 yrs 1 a.a. different Yes No 93 % 3R + 4R (6) Yes Yes
Mouse 2 yrs 3 a.a. different No No 89 % 4R (3) No No
aparenthesis indicate the number of total tau isoforms; yrs, years; a.a., amino acid(s); ND, no data
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had been reported to have seizures. Also, we performed
full necropsy of all the cases and did not find lesions that
would cause seizures, thus AT8-positivity and the severe
neuronal loss are not related to seizure activity in cats.
Conclusions
It has been argued that the pathology observed in Tg
mice harboring mutations in their APP, PSEN, and/or
MAPT is different from that seen in human AD, prob-
ably due to the abnormally high expression levels and/or
altered aggregation properties of Aβ and tau [13, 14, 41,
46]. Non-Tg animals, such as monkeys and dogs, de-
velop SP composed of human-type Aβ as they age, but
these animals do not experience NFT-induced neurode-
generation. Here, we demonstrated that domestic cats
spontaneously develop Aβ deposition, NFT formation,
and neuronal loss, during their shorter life-span (about
20 years) than that of humans. Based on these patho-
logical features of aged cat brains, we propose that do-
mestic cats could be a valuable natural animal model of
human AD, as aged cats display Aβ and tau pathologies
earlier than humans, and thus, would be useful for in-
vestigating the pathogenesis of and possible treatments
for the disease.
Additional file
Additional file 1: Figure S1. Aβ deposition in cat brains. (a)
Immunohistochemistry of the cerebrum of a 17-year-old cat (case No. 20)
for Aβ42 with FA pretreatment. Aβ42 aggregates are observed in the
cerebral cortex but not in the hippocampus by immunohistochemistry
with FA pretreatment. Higher magnification of the parietal lobe (right).
Bar = 100 μm. (b) Negative control (without primary antibody) of Fig. 1c.
No staining is detected in the cytoplasm. (c) ELISA for high molecular
weight Aβ oligomers. Higher amounts of Aβ oligomers were seen in the
brains of aged cats (15-year-old, case No. 15; 17-year-old, case No. 20)
compared to the brains of young cats (3-year-old, case No. 5; 3-year-old,
case No. 6). The ratio of MAP level per unit of Aβ concentration varies
depending on the sizes of the Aβ oligomers. One pM of the MAP can be
estimated to yield the same signal as 1.56 pM (for 20-mer) to 5.0
pM (for 100-mer) of Aβ42 oligomers [33]. Ctx, cortex; Hpc, hippocampus.
Figure S2 Western blotting analysis of the SDS fraction of the cortex (Ctx)
and hippocampus (Hpc) of young cats and aged cats. (a) The band
corresponding to Aβ dodecamer is detected by anti-Aβ antibody 82E1. (b)
Aβ oligomers that are demonstrated in Fig. 1f are not detected by
anti-ApoE antibody A299. Figure S3 Expression of tau isoforms in the
developing cat brain. (a) Immunohistochemistry of the hippocampus CA1
region of a fetus (case No. 1), a 2-week-old cat (case No. 3), and a 4-year-old
cat (case No. 7) for 3-repeat tau (RD3), 4-repeat tau (RD4), and
hyperphosphorylated tau (AT8). Only the 3-repeat tau isoform is
expressed in the fetal hippocampus. The hippocampal pyramidal cells begin
to express 4-repeat tau in the 2-week-old cat (arrows). Both 3-repeat and
4-repeat tau isoforms are expressed in the hippocampus of adult cat brain.
Bar = 50 μm. (b) Immunohistochemistry of the cerebral cortex of a fetal cat for
hyperphosphorylated tau (AT8 and AT100). The surface layer of the fetal
cerebral cortex is positive for AT8 and negative for AT100. Bar = 100 μm.
Table S1 Aβ protein amino acid sequences of different animal species.
Table S2 Tau protein amino acid sequences of different animal species.
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